Investor Presentation
42
Investor presentation First six months of 2022
GLP-1 effect dependent on blood glucose level
GLP-1 mechanism of action when blood
sugar levels increase
Semaglutide holds a plethora of therapeutic opportunities¹
Reduces
glucagon
secretion in
the liver
1 List is not exhaustive
Creates sense of satiety in the brain
Brain
GLP-1
Liver
Gut
Slows
gastric
emptying in
the gut
NASH
CKD
Pancreas
Increases insulin secretion in the
pancreas
Diabetes
CVD
FOCUS - Diabetic retinopathy outcomes trial
Semaglutide s.c; ~1,500 patients, T2D ≥10 years
SOUL - Cardiovascular outcomes trial
Oral semaglutide; ~9,600 patients, T2D, established CVD or CKD
SELECT - Cardiovascular outcomes trial
Obesity Semaglutide 2.4 mg, ~17,500 patients with obesity and without
diabetes, event driven
PAD
Brain
disorders
Heart
Failure
Semaglutide in NASH
Semaglutide s.c.; phase 3 and 2 trials
FLOW - Chronic kidney disease outcomes trial
Semaglutide 1.0 mg; ~3,200 patients, T2D, moderate to severe CKD
STRIDE - Peripheral artery disease trial
Semaglutide 1.0 mg; ~ 800 patients with T2D and PAD
Alzheimer's Disease
Oral Semaglutide 14 mg; ~ 3,700 patients with early Alzheimer's
disease
STEP - HFPEF
Semaglutide 2.4 mg; ~ 600 patients with obesity-related HFPEF
Sc: Subcutaneous; T2D: Type 2 diabetes; CVD: Cardiovascular disease; CKD: Chronic kidney disease; NASH: Non-alcoholic steatohepatitis; PAD: Peripheral artery disease
Novo NordiskⓇView entire presentation